Abstract
Summary
Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists, AT1 receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
LPI (LP Information)' newest research report, the “Angiotensin Receptor Blockers (ARBs) Industry Forecast” looks at past sales and reviews total world Angiotensin Receptor Blockers (ARBs) sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiotensin Receptor Blockers (ARBs) sales for 2023 through 2029. With Angiotensin Receptor Blockers (ARBs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiotensin Receptor Blockers (ARBs) industry.
This Insight Report provides a comprehensive analysis of the global Angiotensin Receptor Blockers (ARBs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiotensin Receptor Blockers (ARBs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiotensin Receptor Blockers (ARBs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiotensin Receptor Blockers (ARBs) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiotensin Receptor Blockers (ARBs).
The global Angiotensin Receptor Blockers (ARBs) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Angiotensin Receptor Blockers (ARBs) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Angiotensin Receptor Blockers (ARBs) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Angiotensin Receptor Blockers (ARBs) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Angiotensin Receptor Blockers (ARBs) players cover Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin Receptor Blockers (ARBs) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segmentation by application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Angiotensin Receptor Blockers (ARBs) market?
What factors are driving Angiotensin Receptor Blockers (ARBs) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Angiotensin Receptor Blockers (ARBs) market opportunities vary by end market size?
How does Angiotensin Receptor Blockers (ARBs) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Angiotensin Receptor Blockers (ARBs) Industry Forecast” looks at past sales and reviews total world Angiotensin Receptor Blockers (ARBs) sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiotensin Receptor Blockers (ARBs) sales for 2023 through 2029. With Angiotensin Receptor Blockers (ARBs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Angiotensin Receptor Blockers (ARBs) industry.
This Insight Report provides a comprehensive analysis of the global Angiotensin Receptor Blockers (ARBs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiotensin Receptor Blockers (ARBs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiotensin Receptor Blockers (ARBs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiotensin Receptor Blockers (ARBs) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiotensin Receptor Blockers (ARBs).
The global Angiotensin Receptor Blockers (ARBs) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Angiotensin Receptor Blockers (ARBs) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Angiotensin Receptor Blockers (ARBs) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Angiotensin Receptor Blockers (ARBs) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Angiotensin Receptor Blockers (ARBs) players cover Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb and Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin Receptor Blockers (ARBs) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Valsartan
Telmisartan
Losartan
Irbesartan
Azilsartan
Olmesartan
Segmentation by application
Hypertension
Cardiovascular Diseases
Kidney Diseases
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol-Myers Squibb
Bayer
GSK
Teva Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Angiotensin Receptor Blockers (ARBs) market?
What factors are driving Angiotensin Receptor Blockers (ARBs) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Angiotensin Receptor Blockers (ARBs) market opportunities vary by end market size?
How does Angiotensin Receptor Blockers (ARBs) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Angiotensin Receptor Blockers (ARBs) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Angiotensin Receptor Blockers (ARBs) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Angiotensin Receptor Blockers (ARBs) by Country/Region, 2018, 2022 & 2029
2.2 Angiotensin Receptor Blockers (ARBs) Segment by Type
2.2.1 Valsartan
2.2.2 Telmisartan
2.2.3 Losartan
2.2.4 Irbesartan
2.2.5 Azilsartan
2.2.6 Olmesartan
2.3 Angiotensin Receptor Blockers (ARBs) Sales by Type
2.3.1 Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Type (2018-2023)
2.3.2 Global Angiotensin Receptor Blockers (ARBs) Revenue and Market Share by Type (2018-2023)
2.3.3 Global Angiotensin Receptor Blockers (ARBs) Sale Price by Type (2018-2023)
2.4 Angiotensin Receptor Blockers (ARBs) Segment by Application
2.4.1 Hypertension
2.4.2 Cardiovascular Diseases
2.4.3 Kidney Diseases
2.4.4 Other
2.5 Angiotensin Receptor Blockers (ARBs) Sales by Application
2.5.1 Global Angiotensin Receptor Blockers (ARBs) Sale Market Share by Application (2018-2023)
2.5.2 Global Angiotensin Receptor Blockers (ARBs) Revenue and Market Share by Application (2018-2023)
2.5.3 Global Angiotensin Receptor Blockers (ARBs) Sale Price by Application (2018-2023)
3 Global Angiotensin Receptor Blockers (ARBs) by Company
3.1 Global Angiotensin Receptor Blockers (ARBs) Breakdown Data by Company
3.1.1 Global Angiotensin Receptor Blockers (ARBs) Annual Sales by Company (2018-2023)
3.1.2 Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Company (2018-2023)
3.2 Global Angiotensin Receptor Blockers (ARBs) Annual Revenue by Company (2018-2023)
3.2.1 Global Angiotensin Receptor Blockers (ARBs) Revenue by Company (2018-2023)
3.2.2 Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Company (2018-2023)
3.3 Global Angiotensin Receptor Blockers (ARBs) Sale Price by Company
3.4 Key Manufacturers Angiotensin Receptor Blockers (ARBs) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Angiotensin Receptor Blockers (ARBs) Product Location Distribution
3.4.2 Players Angiotensin Receptor Blockers (ARBs) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Angiotensin Receptor Blockers (ARBs) by Geographic Region
4.1 World Historic Angiotensin Receptor Blockers (ARBs) Market Size by Geographic Region (2018-2023)
4.1.1 Global Angiotensin Receptor Blockers (ARBs) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Angiotensin Receptor Blockers (ARBs) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Angiotensin Receptor Blockers (ARBs) Market Size by Country/Region (2018-2023)
4.2.1 Global Angiotensin Receptor Blockers (ARBs) Annual Sales by Country/Region (2018-2023)
4.2.2 Global Angiotensin Receptor Blockers (ARBs) Annual Revenue by Country/Region (2018-2023)
4.3 Americas Angiotensin Receptor Blockers (ARBs) Sales Growth
4.4 APAC Angiotensin Receptor Blockers (ARBs) Sales Growth
4.5 Europe Angiotensin Receptor Blockers (ARBs) Sales Growth
4.6 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Growth
5 Americas
5.1 Americas Angiotensin Receptor Blockers (ARBs) Sales by Country
5.1.1 Americas Angiotensin Receptor Blockers (ARBs) Sales by Country (2018-2023)
5.1.2 Americas Angiotensin Receptor Blockers (ARBs) Revenue by Country (2018-2023)
5.2 Americas Angiotensin Receptor Blockers (ARBs) Sales by Type
5.3 Americas Angiotensin Receptor Blockers (ARBs) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Angiotensin Receptor Blockers (ARBs) Sales by Region
6.1.1 APAC Angiotensin Receptor Blockers (ARBs) Sales by Region (2018-2023)
6.1.2 APAC Angiotensin Receptor Blockers (ARBs) Revenue by Region (2018-2023)
6.2 APAC Angiotensin Receptor Blockers (ARBs) Sales by Type
6.3 APAC Angiotensin Receptor Blockers (ARBs) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Angiotensin Receptor Blockers (ARBs) by Country
7.1.1 Europe Angiotensin Receptor Blockers (ARBs) Sales by Country (2018-2023)
7.1.2 Europe Angiotensin Receptor Blockers (ARBs) Revenue by Country (2018-2023)
7.2 Europe Angiotensin Receptor Blockers (ARBs) Sales by Type
7.3 Europe Angiotensin Receptor Blockers (ARBs) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Angiotensin Receptor Blockers (ARBs) by Country
8.1.1 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales by Country (2018-2023)
8.1.2 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Revenue by Country (2018-2023)
8.2 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales by Type
8.3 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Angiotensin Receptor Blockers (ARBs)
10.3 Manufacturing Process Analysis of Angiotensin Receptor Blockers (ARBs)
10.4 Industry Chain Structure of Angiotensin Receptor Blockers (ARBs)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Angiotensin Receptor Blockers (ARBs) Distributors
11.3 Angiotensin Receptor Blockers (ARBs) Customer
12 World Forecast Review for Angiotensin Receptor Blockers (ARBs) by Geographic Region
12.1 Global Angiotensin Receptor Blockers (ARBs) Market Size Forecast by Region
12.1.1 Global Angiotensin Receptor Blockers (ARBs) Forecast by Region (2024-2029)
12.1.2 Global Angiotensin Receptor Blockers (ARBs) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Angiotensin Receptor Blockers (ARBs) Forecast by Type
12.7 Global Angiotensin Receptor Blockers (ARBs) Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.1.3 Pfizer Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.2.3 Novartis Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Merck
13.3.1 Merck Company Information
13.3.2 Merck Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.3.3 Merck Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Merck Main Business Overview
13.3.5 Merck Latest Developments
13.4 Astra Zeneca
13.4.1 Astra Zeneca Company Information
13.4.2 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.4.3 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Astra Zeneca Main Business Overview
13.4.5 Astra Zeneca Latest Developments
13.5 Jhonson and Johnson
13.5.1 Jhonson and Johnson Company Information
13.5.2 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.5.3 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Jhonson and Johnson Main Business Overview
13.5.5 Jhonson and Johnson Latest Developments
13.6 Eli Lilly
13.6.1 Eli Lilly Company Information
13.6.2 Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.6.3 Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Eli Lilly Main Business Overview
13.6.5 Eli Lilly Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.7.3 Sanofi Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 Bristol-Myers Squibb
13.8.1 Bristol-Myers Squibb Company Information
13.8.2 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.8.3 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Bristol-Myers Squibb Main Business Overview
13.8.5 Bristol-Myers Squibb Latest Developments
13.9 Bayer
13.9.1 Bayer Company Information
13.9.2 Bayer Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.9.3 Bayer Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Bayer Main Business Overview
13.9.5 Bayer Latest Developments
13.10 GSK
13.10.1 GSK Company Information
13.10.2 GSK Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.10.3 GSK Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 GSK Main Business Overview
13.10.5 GSK Latest Developments
13.11 Teva Pharmaceutical
13.11.1 Teva Pharmaceutical Company Information
13.11.2 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Portfolios and Specifications
13.11.3 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Teva Pharmaceutical Main Business Overview
13.11.5 Teva Pharmaceutical Latest Developments
14 Research Findings and Conclusion